This analysis showed that, as a whole, H3K4me1 peaks in the MLL3 KD, but not in the control, are enriched for the Creighton “group 4 set” of genes associated with acquired endocrine therapy resistance in breast tumors (Figure 2C).31 The gene discussed is KMT2C; the disease is breast neoplasm.